By Gina Shaw
A pharmacogenetic test to guide treatment decisions for major depressive disorder (MDD) resulted in cost savings and improved quality-adjusted life-years (QALYs), according to a new analysis by researchers at the University of California, San Diego (UCSD) (J Manag Care Spec Pharm 2018;24[8]:726-734).
The IDgenetix (IDGx; AltheaDx) test uses a panel of 10 genes, along with concomitant medications, to make medication management recommendations for more than 40 medications used to treat